GlassScriptPhysician profile
Natale T Sheehan
NPI 1518178524
$3,996.57
in general payments reported to CMS, 2019-2025
51 companies · $1,205 in 2025
The $1,205 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $111 · 2021: $523 · 2022: $509 · 2023: $586 · 2024: $594 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $420.80 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Celgene Corporation | $389.16 | 2021-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $314.86 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $225.55 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $224.87 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Gilead Sciences, INC. | $221.85 | 2021-2024 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $207.02 | 2023-2025 | Calquence, Enhertu, Imfinzi |
| Genentech USA, INC. | $205.14 | 2019-2025 | Venclexta, Polivy, Itovebi |
| Array Biopharma INC | $160.27 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $118.02 | 2019-2024 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $114.88 | 2021-2023 | Imbruvica |
| Kite Pharma, INC. | $114.77 | 2021-2025 | Yescarta |
| Genzyme Corporation | $91.74 | 2023-2025 | |
| Eisai INC. | $87.06 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $76.41 | 2021-2025 |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natale Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.